The Design and Synthesis of Potent and Selective Inhibitors of Trypanosoma brucei Glycogen Synthase Kinase 3 for the Treatment of Human African Trypanosomiasis

[Image: see text] Glycogen synthase kinase 3 (GSK3) is a genetically validated drug target for human African trypanosomiasis (HAT), also called African sleeping sickness. We report the synthesis and biological evaluation of aminopyrazole derivatives as Trypanosoma brucei GSK3 short inhibitors. Low n...

Descripción completa

Detalles Bibliográficos
Autores principales: Urich, Robert, Grimaldi, Raffaella, Luksch, Torsten, Frearson, Julie A., Brenk, Ruth, Wyatt, Paul G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175002/
https://www.ncbi.nlm.nih.gov/pubmed/25198388
http://dx.doi.org/10.1021/jm500239b

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175002/
https://www.ncbi.nlm.nih.gov/pubmed/25198388
http://dx.doi.org/10.1021/jm500239b

Ejemplares similares